
Gertjan Rasschaert/LinkedIn
Jun 28, 2025, 09:12
Gertjan Rasschaert: AZUR-4 Trial on Neoadjuvant Immunotherapy in MSS Colon Cancer
Gertjan Rasschaert, Medical Doctor and Consultant specializing in Gastrointestinal Oncology and Gastroenterology at UZ Leuven, shared a post on LinkedIn:
“AZUR-4 is open in 10 centers in Belgium: neoadjuvant immunotherapy in pMMR/MSS CRC.
Thanks MediMix for highlighting our UZ Leuven – KU Leuven trial in progress poster, presented at last month’s American Society of Clinical Oncology (ASCO).
AZUR-4 is a 3:1 randomized phase 2/3 study (NCT06091254) investigating the use of neoadjuvant dostarlimab in combination with capecitabine and oxaliplatin (CAPEOX) compared to CAPEOX alone in previously untreated T4N0 or Stage III mismatch repair proficient (MMRp)/microsatellite stable (MSS) colon cancer.”
More posts featuring Gertjan Rasschaert.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 28, 2025, 09:05
Jun 28, 2025, 07:43
Jun 28, 2025, 07:35
Jun 28, 2025, 07:09
Jun 28, 2025, 06:47
Jun 28, 2025, 06:40